Type 1 diabetes risk was elevated among patients with celiac disease, hypothyroidism, or hyperthyroidism vs control patients.

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...